Long-term open-label perampanel: Generalized tonic-clonic seizures in idiopathic generalized epilepsy.

ABSTRACT:

Objective

Assess the longer-term efficacy and safety of adjunctive perampanel (up to 12 mg/day) in patients aged ≥12 years with generalized tonic-clonic (GTC) seizures from the Open-label Extension (OLEx) Phase of Study 332 to determine whether responses obtained during the Core Study are maintained during long-term treatment.

Methods

Patients with GTC seizures previously enrolled in a randomized placebo-controlled trial of perampanel could enter an OLEx Phase comprising 6-week blinded conversion (during which patients previously randomized to placebo-switched to perampanel) and up to 136-week maintenance periods (maximum perampanel dose of 12 mg/day). A 4-week follow-up period was completed by all patients after the last on-treatment visit during the OLEx. We assessed seizu

SUBMITTER: French JA 

PROVIDER: S-EPMC9436298 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature